Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study

Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study

Abstract Background Patients with V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) V600E-mutated advanced colorectal cancer (CRC) have a poor prognosis, and treatment options that can improve outcome are still under investigation. The purpose of this study was to discuss the differences of over...

Full description

Bibliographic Details
Main Authors:	Qianhao Meng, Jian Zhao, Yuanyuan Yu, Ke Wang, Jing Ren, Chang Xu, Yusheng Wang, Guangyu Wang
Format:	Article
Language:	English
Published:	BMC 2023-02-01
Series:	BMC Cancer
Subjects:	Advanced colorectal cancer BRAF V600E mutation Overall survival Progression-free survival
Online Access:	https://doi.org/10.1186/s12885-023-10640-9

Similar Items

Survival of Patients With Primary Cutaneous Melanoma (Stages 0-IIА and IIB-IIC), Depending on the Presence of the <i>BRAF</i> Mutation in the Tumor and Surgical Treatment Option
by: S. A. Yаrgunin, et al.
Published: (2024-03-01)

BRAF Non-V600 Mutations in Metastatic Colorectal Cancer
by: Junjia Liu, et al.
Published: (2023-09-01)

Incidence and prognostic factors in patents (pts) with mutant BRAF (mBRAF) metastatic colorectal cancer (mCRC) in Russia
by: M. Yu. Fedyanin, et al.
Published: (2021-06-01)

Validation of Immunohistochemistry for the Detection of <i>BRAF</i> V600E-Mutated Lung Adenocarcinomas
by: Chien-Hung Gow, et al.
Published: (2019-06-01)

Clinical research progress in the treatment of BRAF V600 mutation-positive advanced melanoma
by: JIANG Jianyun, YING Hongmei
Published: (2022-05-01)

Prognostic significance of sarcopenia diagnosed based on the anthropometric equation for progression-free survival and overall survival in patients with colorectal cancer
by: Hailun Xie, et al.
Published: (2023-02-01)

Real-World Outcomes of First-Line FOLFIRI Plus Bevacizumab with Irinotecan Dose Escalation versus FOLFOXIRI Plus Bevacizumab in <i>BRAF<sup>V600E</sup></i>-Mutant Metastatic Colorectal Cancer: The Preliminary Data from a Single-Center Observational Study
by: Hsiang-Lin Tsai, et al.
Published: (2023-12-01)

Clinical, Pathological and Prognostic Features of Rare BRAF Mutations in Metastatic Colorectal Cancer (mCRC): A Bi-Institutional Retrospective Analysis (REBUS Study)
by: Maria Alessandra Calegari, et al.
Published: (2021-04-01)

The Impact of <i>BRAF</i> Mutation Status on Survival Outcomes and Treatment Patterns among Metastatic Colorectal Cancer Patients in Alberta, Canada
by: R. Liam Sutherland, et al.
Published: (2023-12-01)

Therapeutic strategies for BRAF mutation in non-small cell lung cancer: a review
by: Megha Puri, et al.
Published: (2023-08-01)

Treatment Outcomes of Metastatic Colorectal Cancer Patients Treated with Regorafenib as Third-Line Setting-A Multicenter Study
by: Süleyman Şahin, et al.
Published: (2019-03-01)

BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers
by: Giorgia Castellani, et al.
Published: (2023-08-01)

The prevalence of KRAS and BRAF mutation in colorectal cancer patients in Bali
by: Ayu Dewi Ni Nyoman, et al.
Published: (2022-03-01)

The possibilities of therapy of patients with metastatic colorectal cancer with <i>BRAF</i> V600E mutation. Clinical cases
by: Elizaveta M. Polyanskaya, et al.
Published: (2023-05-01)

A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study
by: Martina Eriksen, et al.
Published: (2022-12-01)

Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with TwoState-of-the-Art Techniques
by: Nicola L. Schoenewolf, et al.
Published: (2012-06-01)

Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized Therapies
by: Alexander Hendricks, et al.
Published: (2020-02-01)

Colorectal cancer in patients of advanced age is associated with increased incidence of BRAF p.V600E mutation and mismatch repair deficiency
by: Eric S. Christenson, et al.
Published: (2023-06-01)

<i>BRAF</i> Inhibitors in <i>BRAF-Mutated</i> Colorectal Cancer: A Systematic Review
by: Wajeeha Aiman, et al.
Published: (2023-12-01)

Molecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer
by: İvo Gökmen, et al.
Published: (2023-09-01)

Real-world treatment patterns and clinical outcomes for chemotherapy-based regimens in first-line MSI-H/dMMR metastatic colorectal cancer
by: Mayur M. Amonkar, et al.
Published: (2023-01-01)

Comparison of Immunotherapy versus Targeted Therapy Effectiveness in BRAF-Mutant Melanoma Patients and Use of cGAS Expression and Aneuploidy as Potential Prognostic Biomarkers
by: Zachary Garrison, et al.
Published: (2024-03-01)

Clinicopathological Features of Non-Small Cell Lung Carcinoma with BRAF Mutation
by: Andrea Ambrosini-Spaltro, et al.
Published: (2023-11-01)

Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review
by: Morena Fasano, et al.
Published: (2022-01-01)

The prognostic role of tumor mutation burden on survival of breast cancer: a systematic review and meta-analysis
by: Liyuan Ke, et al.
Published: (2022-11-01)

Development and validation of prognostic nomograms for overall survival in patients with locally advanced colorectal cancer
by: Huwei Nie, et al.
Published: (2024-01-01)

Prevalence of BRAF V600E Mutation in the Iranian Patients with Hairy Cell Leukemia: A Retrospective Study
by: Mojtaba Karimi, et al.
Published: (2021-06-01)

PROMISES FOR TREATING COLON CANCER PATIENTS WITH BRAF GENE MUTATION
by: M. Yu. Fedyanin, et al.
Published: (2015-02-01)

BRAF mutation in colorectal cancer: An update
by: Colombo Alfredo, et al.
Published: (2023-01-01)

BRAF V600E Mutation in Malignant Melanoma—A Romanian Research Experience
by: Elena-Roxana Avădănei, et al.
Published: (2024-02-01)

Survival analysis for complicated colorectal cancer
by: S. N. Schaeva
Published: (2017-09-01)

Construction and validation of a nomogram model for predicting the overall survival of colorectal cancer patients
by: Guo Peiyuan, et al.
Published: (2023-06-01)

Survival Analysis of Lung Adenocarcinoma Patients with Exon 19 Del and 21 L858R Mutations Receiving EGFR-TKI Treatment
by: Stephen Johan Prasetyo, et al.
Published: (2023-05-01)

Characterization of BRAF mutation in patients older than 45 years with well-differentiated thyroid carcinoma
by: Luis Rene Quiroa Barreno, et al.
Published: (2022-07-01)

Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study
by: Shigeo Shimose, et al.
Published: (2022-09-01)

The Prognostic Significance of Thymidine Kinase Activity Levels In Metastatic Colorectal Cancer
by: Erdoğan Selçuk ŞEBER
Published: (2016-12-01)

Diagnostic and prognostic role of long non-coding RNAs (lncRNAs) in metastatic melanoma patients with BRAF gene mutation receiving BRAF and MEK inhibitors
by: Łukasz Galus, et al.
Published: (2024-04-01)

Serum creatinine/cystatin C ratio as a prognostic indicator for patients with colorectal cancer
by: Shunhui Gao, et al.
Published: (2023-06-01)

Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma
by: Alessandro Nepote, et al.
Published: (2022-02-01)

Is there a prognostic difference among stage I lung adenocarcinoma patients with different BRAF‐mutation status?
by: Shang‐Shang Ma, et al.
Published: (2024-03-01)